1 王鑫龙,孙备.中国抗癌协会胰腺癌综合诊治指南(2018版)更新解读[J].临床外科杂志,2019,27(1):21-24. 2 Wagner M,Redaelli C,Lietz M,et al.Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma[J].Br J Surg,2004,91(5):586-594. 3 Riediger H,Keck T,Wellner U,et al.The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer[J].J Gastrointest Surg,2009,13(7):1337-1344. 4 Kovaˇc JD,Mayer P,Hackert T,et al.The time to and type of pancreatic cancer recurrence after surgical resection:Is prediction possible?[J].Acad Radiol,2019,26(6):775-781. 5 Bakkevold KE,Arnesj B,Dahl O,et al.Adjuvant combination chemotherapy(AMF)following radical resection of carcinoma of the pancreas and papilla of vater-results of a controlled,prospective,randomised multicentre study[J].Eur J Cancer,1993,29(5):698-703. 6 Neoptolemos JP,Dunn JA,Stocken DD,et al.Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer:a randomised controlled trial[J].Lancet,2001,358(9293):1576-1585. 7 Oettle H,Neuhaus P,Hochhaus A,et al.Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer:the CONKO-001 randomized trial[J].JAMA,2013,310(14):1473-1481. 8 Ueno H,Kosuge T,Matsuyama Y,et al.A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer:Japanese study group of adjuvant therapy for pancreatic cancer[J].Eur J Cancer,2016,101(6):96-103. 9 Sudo K,Nakamura K,Yamaguchi T.S-1 in the treatment of pancreatic cancer[J].World J Gastroenterol,2014,20(41):15110-15118. 10 Yokoyama H,Nakanishi H,Kodera Y.Biological significance of isolated tumor cells and micrometastasis in lymph nodes evaluated using a green fuorescent protein tagged human gastric cancer cell line[J].Clin Cancer Res,2006,12(2):361-368. 11 Davendra PS.Adjuvant and neoadjuvant therapy for resectable pancreatic adenocarcinoma[J].Chin Clin Oncol,2017,6(3):26. 12 Ueno H,Kosuge T,Matsuyama Y,et al.A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer:Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer[J].Br J Cancer,2009,101(6):908-915. 13 Greenhalf W,Ghaneh P,Neoptolemos JP,et al.Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial[J].J Natl Cancer Inst,2014,106(1):347. 14 Valle JW,Palmer D,Jackson R,et al.Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas:ongoing lessons from the ESPAC-3 study[J].J Clin Oncol,2014,32(6):504-512. 15 Murakami Y,Uemura K,Hashimoto Y,et al.Survival effects of adjuvant gemcitabine plus S-1 chemotherapy on pancreatic carcinoma stratified by preoperative resectability status[J].J Surg Oncol,2016,113(4):405-412. 16 Xu JB,Jiang B,Chen Y,et al.Optimal adjuvant chemotherapy for resected pancreatic adenocarcinoma:a systematic review and network meta-analysis[J].Oncotarget,2017,8(46):81419-81429. 17 Kosuge T.A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer[J].Jpn J Clin Oncol,2006,36(3):159-165. 18 Postlewait LM,Ethun CG,Kooby DA,et al.Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma:results of a phase II prospective trial[J].J Surg Oncol,2016,114(3):336-341. 19 Khorana AA,McKenin SE,Berlin J,et al.Potentially curable pancreatic adenocarcinoma:ASCO clinical practice guideline update[J].J Clin Oncol,2019,37(23):2082-2088. 20 Antoniou G,Kountourakis P,Papadimitriou K,et al.Adjuvant therapy for resectable pancreatic adenocarcinoma:Review of the current treatment approaches and future directions[J].Cancer Treat Rev,2014,40(1):78-85. 21 Sinn M,Bahra M,Liersch T,et al.CONKO-005:Adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer:a multicenter randomized phase III Trial[J].J Clin Oncol,2017,35(29):3330-3337. 22 Shultz DB,Pai J,Chiu W,et al.A novel biomarker panel examining response to gemcitabine with or without Erlotinib for pancreatic cancer therapy in NCIC Clinical Trials Group PA.3[J].PLoS One,2016,11(1):e0147995. 23 Sinn M,Liersch T,Gellert K,et al.LBA18CONKO-006:a randomized double-blinded phase IIb-study of additive therapy with gemcitabine plus Sorafenib/Placebo for patients with R1-resection of pancreatic cancer[J].Ann Oncol,2014,25(suppl4):1-8. 24 Fenster H,Schade-Brittingger C,Muller HH,et al.Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer(ATIP)[J].Ann Oncol,2013,24(10):2576-2581. 25 Sun D,Ma J,et al.Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer:a real-world study in Chinese cohort[J].Ther Clin Risk Manag,2018,14:1691-1700. 26 Bahary N,Wang-Gillam A,Haraldsdottir S,et al.Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of patients with metastatic pancreas cancer[R].ASCO,2018. 27 Miyazawa M,Katsuda M,Maguchi H,et al.Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients[J].Int J Cancer,2017,140(4):973-982. 28 Lutz E,Yeo CJ,Lillemoe KD,et al.A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma.A Phase II trial of safety,efficacy,and immune activation[J].Ann Surg,2011,253(2):328-335. 29 Hardacre JM,Mulcahy M,Small W,et al.Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer:a phase 2 study[J].J Gastrointest Surg,2013,17(1):94-100. 30 Tsai S,Erickson BA,Dua K,et al.Evolution of the management of resectable pancreatic cancer[J].J Oncol Pract,2016,12(9):772-778. 31 Comito T,Cozzi L,Zerbi A,et al.Clinical results of stereotactic body radiotherapy(SBRT)in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery:A retrospective study[J].Eur J Surg Oncol,2017,43(4):735-742. 32 Motoi F,Kosuge T,Ueno H,et al.Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer(Prep-02/JSAP05)[J].Jpn J Clin Oncol,2019,49(2):190-194. |